News on ChemoCentryx%2C Inc. from BioPortfolio.com http://www.BioPortfolio.com Consolidated ChemoCentryx%2C Inc. news from BioPortfolio.com Wed, 10 Feb 2010 07:39:54 GMT en Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028852&HITNO=0&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028852&THISHREF=http://c.moreover.com/click/here.pl%3fz2532868617%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028852&HITNO=0&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028852&THISHREF=http://c.moreover.com/click/here.pl%3fz2532868617%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: ChemoCentryx initiates Phase I study of autoimmune drug - Zibb.co...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992161&HITNO=1&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992161&THISHREF=http://c.moreover.com/click/here.pl%3fz2514034409%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3992161&HITNO=1&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3992161&THISHREF=http://c.moreover.com/click/here.pl%3fz2514034409%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: ChemoCentryx initiates Phase I study of autoimmune drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991820&HITNO=2&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991820&THISHREF=http://c.moreover.com/click/here.pl%3fz2513886391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3991820&HITNO=2&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3991820&THISHREF=http://c.moreover.com/click/here.pl%3fz2513886391%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988372&HITNO=3&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988372&THISHREF=http://c.moreover.com/click/here.pl%3fz2510955659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988372&HITNO=3&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988372&THISHREF=http://c.moreover.com/click/here.pl%3fz2510955659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Medical News: ChemoCentryx Initiates Clinical Trial Of CCX168, A Novel Small Molecule C5aR Antagonist For The Treatment Of Inflammatory And Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983178&HITNO=4&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983178&THISHREF=http://c.moreover.com/click/here.pl%3fz2507703568%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983178&HITNO=4&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983178&THISHREF=http://c.moreover.com/click/here.pl%3fz2507703568%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Medical News: ChemoCentryx Initiates Clinical Trial Of CCX168, A Novel Small Molecule C5aR Antagonist For The Treatment Of Inflammatory And Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983174&HITNO=5&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983174&THISHREF=http://c.moreover.com/click/here.pl%3fz2507703138%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983174&HITNO=5&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983174&THISHREF=http://c.moreover.com/click/here.pl%3fz2507703138%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Medical News: ChemoCentryx Initiates Clinical Trial Of CCX168, A Novel Small Molecule C5aR Antagonist For The Treatment Of Inflammatory And Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983170&HITNO=6&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983170&THISHREF=http://c.moreover.com/click/here.pl%3fz2507702961%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983170&HITNO=6&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983170&THISHREF=http://c.moreover.com/click/here.pl%3fz2507702961%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Ihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981249&HITNO=7&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981249&THISHREF=http://c.moreover.com/click/here.pl%3fz2506877096%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981249&HITNO=7&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981249&THISHREF=http://c.moreover.com/click/here.pl%3fz2506877096%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980271&HITNO=8&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980271&THISHREF=http://c.moreover.com/click/here.pl%3fz2506298081%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980271&HITNO=8&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980271&THISHREF=http://c.moreover.com/click/here.pl%3fz2506298081%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: ChemoCentryx Initiates Clinical Trial Of CCX168, A Novel Small Molecule C5aR Antagonist For The Treatment Of Ihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3982123&HITNO=9&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3982123&THISHREF=http://c.moreover.com/click/here.pl%3fz2507346546%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3982123&HITNO=9&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3982123&THISHREF=http://c.moreover.com/click/here.pl%3fz2507346546%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: ChemoCentryx announces the initiation of Phase I clinical trial of CCX168http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980538&HITNO=10&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980538&THISHREF=http://c.moreover.com/click/here.pl%3fz2506452968%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980538&HITNO=10&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980538&THISHREF=http://c.moreover.com/click/here.pl%3fz2506452968%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: ChemoCentryx Initiates Novel Autoimmune Trialshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981723&HITNO=11&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981723&THISHREF=http://c.moreover.com/click/here.pl%3fz2507167625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981723&HITNO=11&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981723&THISHREF=http://c.moreover.com/click/here.pl%3fz2507167625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Technology: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977816&HITNO=12&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977816&THISHREF=http://c.moreover.com/click/here.pl%3fz2504977190%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977816&HITNO=12&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977816&THISHREF=http://c.moreover.com/click/here.pl%3fz2504977190%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3978153&HITNO=13&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3978153&THISHREF=http://c.moreover.com/click/here.pl%3fz2505133060%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3978153&HITNO=13&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3978153&THISHREF=http://c.moreover.com/click/here.pl%3fz2505133060%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Ihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976553&HITNO=14&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976553&THISHREF=http://c.moreover.com/click/here.pl%3fz2504420478%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976553&HITNO=14&MSIZE=74&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ChemoCentryx,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976553&THISHREF=http://c.moreover.com/click/here.pl%3fz2504420478%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: